Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuritis Clear all
Completed Phase 1 Interventional

Safety and Tolerability of Rituximab in Neuromyelitis Optica

NCT00501748
View directory record Official record
Conditions
Neuromyelitis Optica
Interventions
Rituximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 86 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
San Francisco, California • Columbia University Medical Center 710 West 168th Street,, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Sep 9, 2026, 6:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.

NCT03942952
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Transverse Myelitis
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 21 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2023 · Synced Sep 9, 2026, 6:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Evaluation of a Novel Balance, Vestibular and Oculomotor Assessment Tool

NCT02171312
View directory record Official record
Conditions
Mild Concussion, Post Concussion Syndrome, Vestibular Neuritis
Interventions
iDETECT Assessment, Routine Balance and Vestibular Testing
Device · Behavioral
Lead sponsor
Emory University
Other
Eligibility
12 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 9, 2026, 6:14 AM EDT
Completed No phase listed Observational

Maintenance Plasma Exchange for Neuromyelitis Optica

NCT01500681
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Recurrent Idiopathic Longitudinally Extensive Transverse Myelitis
Interventions
Plasma exchange (PLEX)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 26, 2021 · Synced Sep 9, 2026, 6:14 AM EDT
Recruiting Phase 2 Interventional

Efgartigimod for the Treatment of Acute Optic Neuritis

NCT06453694
View directory record Official record
Conditions
Optic Neuritis
Interventions
Efgartigimod Alfa, Placebo
Drug
Lead sponsor
Anastasia Vishnevetsky, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 9, 2026, 6:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Hematopoietic Stem Cell Transplant in Devic's Disease

NCT00787722
View directory record Official record
Conditions
Devic's Disease
Interventions
Hematopoietic Stem Cell Transplantation, Cyclophosphamide, G-CSF, rATG, Mesna, Rituximab, Methylprednisolone
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Sep 9, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

High Frequency Impulse Therapy for Neuropathic Pain in NMOSD

NCT04614454
View directory record Official record
Conditions
Neuromyelitis Optica
Interventions
High Frequency Impulse Therapy, High Frequency Impulse Therapy - Sham
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 9, 2026, 6:14 AM EDT
Completed Phase 2 Interventional

Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis

NCT00772525
View directory record Official record
Conditions
Multiple Sclerosis, Optic Nerve, Neuritis
Interventions
Nerispirdine, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 9, 2026, 6:14 AM EDT
Completed Early Phase 1 Interventional

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

NCT05291286
View directory record Official record
Conditions
Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
Interventions
BXQ-350, Placebo
Drug · Other
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 9, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Results available

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

NCT02276963
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Ublituximab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Sep 9, 2026, 6:14 AM EDT
Terminated Phase 3 Interventional Results available

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

NCT01892345
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Eculizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
19
States / cities
Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 9, 2026, 6:14 AM EDT
Enrolling by invitation Not applicable Interventional

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder

NCT06374264
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
MR-C-014
Device
Lead sponsor
MedRhythms, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 9, 2026, 6:14 AM EDT
Terminated No phase listed Observational

Diagnosis of ON With or Without MS or NMOSD

NCT04131764
View directory record Official record
Conditions
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Neuromyelitis Optica Spectrum Disorder Relapse, Neuromyelitis Optica Spectrum Disorder Progression, Optic Neuritis
Interventions
Reflex (Brightlamp Inc., Purdue University)
Diagnostic Test
Lead sponsor
Jagannadha R Avasarala
Other
Eligibility
18 Years to 90 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 9, 2026, 6:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Identify the Genetic Variations Associated With Phantom Limb Pain

NCT01462448
View directory record Official record
Conditions
Phantom Limb
Interventions
Blood Draw
Procedure
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 9, 2026, 6:14 AM EDT
Completed Not applicable Interventional

Exercise and Nutrition Interventions During Chemotherapy

NCT03021174
View directory record Official record
Conditions
Neuropathy;Peripheral
Interventions
EXCAP Exercise, Nutrition Education Control
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 9, 2026, 6:14 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Ampyra for Optic Neuritis in Multiple Sclerosis

NCT01337986
View directory record Official record
Conditions
Multiple Sclerosis, Optic Neuritis
Interventions
Dalfampridine/Placebo, Placebo/Dalfampridine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 9, 2026, 6:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Feasibility and Clinical Utility of Paired Non-Invasive Hemodynamic and Tissue Oximetry Monitoring to Detect Limb Ischemia in Lithotomy-Positioned Surgeries

NCT07387653
View directory record Official record
Conditions
Neuropathy;Peripheral, Limb Ischemia
Interventions
Lower-Extremity Perfusion Monitoring
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 9, 2026, 6:14 AM EDT
Recruiting No phase listed Observational

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

NCT05909761
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
Interventions
UPLIZNA
Drug
Lead sponsor
Amgen
Industry
Eligibility
15 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 9, 2026, 6:14 AM EDT
Withdrawn No phase listed Observational

MS and NMOSD in African-Americans

NCT04131673
View directory record Official record
Conditions
Multiple Sclerosis, Neuromyelitis Optica
Interventions
Not listed
Lead sponsor
Jagannadha R Avasarala
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 9, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Acute Video-oculography for Vertigo in Emergency Rooms for Rapid Triage (AVERT)

NCT02483429
View directory record Official record
Conditions
Vertigo, Dizziness
Interventions
VRT Care
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Peoria, Illinois • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 9, 2026, 6:14 AM EDT
Not listed Phase 3 Interventional

Optic Neuritis Treatment Trial (ONTT)

NCT00000146
View directory record Official record
Conditions
Multiple Sclerosis, Optic Neuritis
Interventions
Methylprednisolone, Prednisone
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 46 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1988
U.S. locations
15
States / cities
Little Rock, Arkansas • San Francisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2006 · Synced Sep 9, 2026, 6:14 AM EDT
Terminated Phase 4 Interventional

A Trial of Neuroprotection With ACTH in Acute Optic Neuritis

NCT01838174
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACTHAR Gel (ACTH), IV methylprednisolone (steroids)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Sep 9, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

NCT02166346
View directory record Official record
Conditions
Transverse Myelitis, Neuromyelitis Optica, Idiopathic Transverse Myelitis, Myelitis NOS
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 9, 2026, 6:14 AM EDT
Not listed Not applicable Interventional

Stem Cell Ophthalmology Treatment Study

NCT01920867
View directory record Official record
Conditions
Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease, Glaucoma
Interventions
RB (Retrobulbar), ST (Subtenon), IV (Intravenous), IVIT (Intravitreal), IO (Intraocular)
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Westport, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 9, 2026, 6:14 AM EDT